- Home
- ENLV
as 07-26-2024 4:00pm EST
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
| Founded: | 2005 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 28.4M | IPO Year: | 1995 |
| Target Price: | $6.00 | AVG Volume (30 days): | 36.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $4.59 | Next Earning Date: | 08-30-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Enlivex Therapeutics Ltd. News
ENLV Breaking Stock News: Dive into ENLV Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Enlivex Therapeutics Gets Regulatory Nod in Israel to Begin Phase I Trial for Potential Psoriatic Arthritis Treatment
GlobeNewswire
3 days ago
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
ACCESSWIRE
7 days ago
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
MT Newswires
a month ago
Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial
GlobeNewswire
a month ago
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
GlobeNewswire
a month ago
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
GlobeNewswire
a month ago
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
GlobeNewswire
2 months ago
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Compare ENLV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENLV Enlivex Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.